IO Biotech (IOBT) Piper Sandler 36th Annual Healthcare Conference summary

Company overview and platform

• Celebrating 10-year anniversary, currently in phase III with lead assets IO-102, IO-103, targeting IDO and PD-L1.

• T-win platform is a dual mechanism cancer vaccine engaging T cells to target both tumor and immune suppressive cells.

• Platform creates a pro-inflammatory, anti-tumor environment, synergizing with anti-PD-1 therapies.

Lead program and clinical data

• Lead program IO-102/IO-103 targets IDO and PD-L1, combined with pembrolizumab in phase III.

• Early phase I/II melanoma study showed 80% response rate, 50% complete response, and 25.5 months PFS.

• Data led to FDA Breakthrough Therapy designation and direct advancement to phase III.

• Multicenter global phase II studies in additional indications support robustness of initial data.

Phase III trial design and progress

• Phase III trial sample size increased from 300 to over 400 patients, fully powered for PFS with 89% power.

• Interim analysis in September did not meet high statistical significance (p=0.005), but final PFS readout expected in first half of next year.

• Regulatory discussions most advanced in the U.S., with plans for Europe and global markets ongoing.